3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Other
1
Myeloid
1
Lymphoid
1
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Myelodysplastic Syndromes
1
Mucositis
1
Lymphoma, Non-Hodgkin
1
Leukemia, Myeloid, Acute
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Hodgkin Disease
1
Interventions
Imatinib Mesylate
18
Dasatinib
12
Cyclophosphamide
11
fludarabine phosphate
9
nilotinib
8
fludarabine
7
Sirolimus
6
ruxolitinib
5
Tacrolimus
5
Mycophenolic Acid
5
Cytarabine
5
Azacitidine
5
Whole-Body Irradiation
4
Ipilimumab
4
Busulfan
4
Bortezomib
4
thymoglobulin
3
bosutinib
3
belinostat
3
aldesleukin
3
Specimen Handling
3
Nivolumab
3
Interleukin-2
3
Granulocyte Colony-Stimulating Factor
3
Clofarabine
3
CTLA-4 Antigen
3
Antilymphocyte Serum
3
AP 1903 reagent
3
zileuton
2
tozasertib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
×
angiotensin I (1-7)
×
Clear all
NCT01300611
2020-12-08
USBTXA127CBT
Tarix Pharmaceuticals
Phase 1
Terminated
20 enrolled